[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100657493","phase-1-positron-emission-tomography-pet-imaging-of-chemotherapy-induced-cardiotoxicity-100657493",false,"NCT07838649","Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity","PET Imaging of Chemotherapy-Induced Cardiotoxicity","Inclusion Criteria:\n\n* Men and women, 21-99 years of age and any race\n* Normal left ventricular function (left ventricular ejection fraction (LVEF) \\>50%) as determined by echocardiography\n* HER2 positive or negative breast cancer patients or lymphoma patients\n* Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy\n* Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable)\n\nExclusion Criteria:\n\n* Inability to receive and sign informed consent\n* Prior exposure to anthracyclines or other cardiotoxic drug\n* Contraindications to anthracycline chemotherapy\n* Patients with history of myocardial infarction\n* Patients with fasting blood sugar \\>200 mg\u002FdL or \\\u003C70 mg\u002FdL and symptomatic\n* Contraindications to MR imaging (ferromagnetic implants, pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.)\n* Pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 68Ga-Galmydar or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and\u002For hysterectomy.\n* Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as:\n\n  * Inability to lie still or unable to tolerate a supine position with arms up over the head or down at sides for up to a 60-minute PET scan due to chronic back\u002Fshoulder pain or arthritis as assessed by physical examination and\u002For medical history","ALL","21 Years","99 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.",[27,28,29,30,31],"Lymphoma Cancer","Breast Cancer","Cancer of the Breast","Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[33,34,35,36,37,38,39,40],"Positron Emission Tomography (PET)","Cardiotoxicity","Cardiovascular disease","Chemotherapy-induced cardiac dysfunction","Chemotherapy-induced heart failure","Anthracycline","Doxorubicin","Adriamycin","NOT_YET_RECRUITING","2026-09-17",{"date":44,"type":45},"2026-09-24","ACTUAL",{"date":47,"type":21},"2026-11-01",{"date":49,"type":21},"2029-12-12",{"name":51,"class":52},"Washington University School of Medicine","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100595162","virus-associated-tumour-microenvironment-characterisation-and-immunological-mechanisms-of-resistance-to-anti-tumour-treatments-100595162","NCT07028866","Virus-associated Tumour Microenvironment: Characterisation and Immunological Mechanisms of Resistance to Anti-tumour Treatments","Virus-associated Tumour Microenvironment: Characterisation and Immunological Mechanisms of Resistance to Anti-tumour Treatments - A Retrospective Study","VIRONMENT 2","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients followed in one of the following AP-HP clinical departments: Medical oncology - Pitié-Salpêtrière, Clinical haematology - Pitié-Salpêtrière, Hepato-Gastroenterology - Pitié-Salpêtrière, Maxillo-facial surgery - Pitié-Salpêtrière, Radiation oncology - Pitié-Salpêtrière, Pneumology - Tenon, Medical oncology - Tenon, Radiation oncology - Tenon, Medical oncology - Saint-Antoine, Clinical haematology - Saint-Antoine, Pneumology - Bichat, ENT and cervico-facial surgery - Bichat, Pneumology - Cochin, Medical Oncology - HEGP, Medical Oncology - Saint Louis, Pneumology - Ambroise Paré, Medical Oncology - Avicennes\n\nHistologically confirmed diagnosis of :\n\n* HPV-related squamous cell carcinoma of the oropharynx (positive HPV PCR).\n* Non-HPV-related squamous cell carcinoma of the oropharynx (negative HPV PCR).\n* HIV-associated non-small cell lung cancer (NSCLC) (positive HIV serology).\n* HPV-related NSCLC (malignant transformation of recurrent respiratory papillomatosis with positive HPV PCR).\n* NSCLC neither HPV-related (negative HPV PCR) nor HIV-associated (negative HIV serology).\n* Large-cell B lymphoma (diffuse large-cell NOS B lymphoma, high-grade B lymphoma, primary B lymphoma of the central nervous system):\n* Post-transplant lymphoma (PTL) linked or not to Epstein-Barr virus (EBV)(EBER positive or negative on tumour tissue).\n* Associated with HIV (positive HIV serology) and EBV-related or not (positive or negative EBER on tumour tissue).\n* Associated with neither HIV nor EBV (negative HIV serology, negative EBER on negative tumour tissue).\n* HPV-related squamous cell carcinoma of the anal canal (positive HPV PCR) and associated with HIV (positive HIV serology).\n* HPV-related squamous cell carcinoma of the anal canal (positive HPV PCR) not associated with HIV (negative HIV serology).\n* Patients in the virus-associated cancers VS non-virus-associated cancers groups will be matched on important clinical features within the groups:\n* Oropharyngeal squamous cell carcinoma: tumour stage (I\u002FII or III\u002FIV according to 8th TNM (85)), smoking status (smoker or non-smoker) and systemic anti-tumour treatment planned or received (cytotoxic chemotherapy or Immune checkpoint inhibitors (ICI)(anti PD1) or cytotoxic chemotherapy and ICI(anti PD1)).\n* NSCLC: histology (squamous cell carcinoma or adenocarcinoma), tumour stage (I\u002FII or III\u002FIV according to 8th TNM (85)), smoking status (smoker or non-smoker) and systemic anti-tumour treatment planned or received (ICI (anti PD1) or cytotoxic chemotherapy and ICI (anti PD1)).\n* NHL: patients will be matched 2:2 (LPT EBV+ vs EBV- and HIV+ EBV+ vs EBV-) on location (systemic vs brain), performans status (PS 0-1 vs 2-4) for brain lymphomas, and age-adjusted IPI score (LDH, performans status, stage: 0-1 vs 2-3) for systemic lymphomas.\n* Squamous cell carcinoma of the anal canal: tumour stage (I\u002FII or III\u002FIV according to 8th TNM (85)), and anti-tumour treatment planned or received (cytotoxic chemotherapy or cytotoxic chemotherapy and radiotherapy).\n\nFor the analysis of the characteristics of the MET at diagnosis: tumour material (biopsy or surgical specimen) available dating from before the introduction of anti-cancer treatments. This tumour material must come from the tumour's organ of origin for patients in the oropharynx, NSCLC and anal canal cohorts.\n\n* For the analysis of mechanisms of resistance to systemic anti-tumour treatments: tumour material (biopsy or surgical specimen) available from before the introduction of anti-cancer treatments and tumour material (biopsy or surgical specimen) taken after tumour progression under treatment and before the introduction of a new systemic anti-tumour treatment. This tumour material must come from the tumour's organ of origin for patients in the oropharynx, NSCLC and anal canal cohorts.\n* Cancer that has undergone or is due to undergo excision surgery or biopsy.\n* Informed consent to participate signed before any specific study procedure is carried out.\n* Affiliation with the French social security system.\n\nExclusion Criteria:\n\n* Cancers other than those included in the study.\n* For NHL: plasmablastic lymphoma, polymorphic lymphoma, follicular lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, unknown tumour EBV status, unknown HIV status.\n* For lung cancers: NSCLC with histology other than adenocarcinoma or squamous cell carcinoma, small cell lung cancer, EGFR mutation, ALK rearrangement.\n* Absence of tumour material dating from before the start of systemic anti-tumour treatments.\n* For oropharynx, NSCLC and anal canal: tumour material not from the tumour's organ of origin.\n* Tumour material of interest exhausted: insufficient for the analyses planned in the study.\n* For the anal canal, oropharynx and NSCLC cohorts: immunosuppressive treatment (corticosteroids \\\u003C10mg prednisone equivalent per day authorised).\n* Adults under guardianship or curatorship.\n* Refusal to take part in the study","18 Years",{"count":64,"type":21},254,"OBSERVATIONAL","The presence or absence of viruses affects the characteristics of cancer, the response to anti-cancer treatments, and the prognosis of the disease. A cancerous tumor consists of cancerous cells as well as a variety of non-cancerous cells and molecules, collectively known as the tumor microenvironment. By studying these tumor microenvironments and understanding how our immune system interacts with virus-related and non-virus-related cancers, investigators may discover new approaches to developing more effective anti-cancer treatments. This study aims to characterize the tumor microenvironments specifically associated with viruses. This is a non-interventional, ambispective multicentre study with 5 complementary workpackages (WP); WP1 clinic, WP2 anatomopathology, WP3 molecular analysis, WP4 proteomic analyses using image-based mass cytometry on tissue sections coupled to the HYPERION imaging system, and WP5 Bioinformatics and Biostatistics analyses. Medical record data will be collected and used for this research. The biological resources required for the study will be one or two additional blood samples of minimal volume or already available in the various tumour banks participating in the study. Blood samples and archived biopsies will be transported to CIMI by private carrier. Clinical data will be collected exclusively from the patient's computerised medical record and entered into an electronic case report form (e-CRF) by the Clinical Study coordinator in each recruiting department, identified by the investigating physicians.\n\nIn the analysis, investigators will initially compare the virus-associated and non-virus-associated groups by cancer type, but investigators will also be able to set up a global test by stratifying on cancer type. Investigators will use direct comparisons in the counts from the RNASeq analysis, but also compositional analyses. The remaining statistical evaluations will primarily focus on description and exploration, and will be showcased accordingly. These will involve conventional methods such as computing percentages, means, correlations, along with survival analysis techniques like Kaplan-Meier and Cox regression.",[27],[69,70,71,72],"Virus","tumor microenvironment","chemotherapy","immunotherapy","2025-06-18",{"date":75,"type":45},"2025-06-19",{"date":77,"type":21},"2025-09-02",{"date":79,"type":21},"2027-09-01",{"name":81,"class":52},"Assistance Publique - Hôpitaux de Paris"]